RE:RE:RE:RE:RE:Excess of adipose visceral fat causing NAFLD regardless of..Egrifta is not approved for any condition but HIV lipodystrophy yet! although there are many conditions related to viscera adiposity including NAFLD/NASH doctors can't prescribe the drug. If and when the drug gets approved for NASH I believe it is fairly easy to motivate the patients with a late stage liver disease to take the drug which should be easier to administer once they have the F8 approved as compared to SV the new formulation is much more concentrated thus less to be injected and also the multi dose pen injector will make the process more convenient.
PWIB123 wrote: Makes sense. So at what point does someting like Egrifta become a measure a doctor would recommend? I'm assuming this is easiest to recommend for HIV patients, because they already could benefit for other reasons in addition to NAFLD/NASH. For general Nash population, however, what's the point where a doctor says you need to just give in and start taking a drug that's fairly complex to administer?